5xFAD Transgenic Mouse Model

Migration, Crosslink

📖

5xFAD Transgenic Mouse Model

active

wiki page Created: 2026-04-02T07:19:52 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-5xfad-transgenic-mouse

📖 Wiki Page

mechanism2940 wordssynced 2026-04-02

5xFAD Transgenic Mouse Model

Overview

The 5xFAD transgenic mouse model is one of the most widely used and aggressively amyloidogenic Alzheimer's disease (AD) models available for research. This model co-expresses five familial AD mutations in [amyloid precursor protein](/entities/app-protein) (APP) and [presenilin 1](/entities/psen1) (PSEN1), leading to rapid and robust [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaque deposition beginning at a very young age[@oakley2006]. The 5xFAD model has become a cornerstone for amyloid-focused AD research, providing valuable insights into disease mechanisms and therapeutic development[@selkoe2016].

This comprehensive page details the genetic construction, pathological features, behavioral phenotypes, research applications, and limitations of the 5xFAD model. It also covers recent advances and future directions in 5xFAD-based research.

Genetic Construction

Historical Development

The 5xFAD model was generated through co-injection of two transgenes encoding APP and PSEN1 with familial AD mutations under the control of separate neuronal-specific promoters[@oakley2006]. This double-transgenic approach allows for co-expression of multiple disease-causing mutations in the same animal, creating a robust amyloid pathology model.

APP Transgene Mutations

The APP transgene carries three FAD mutations, collectively known as the "Swedish," "Florida," and "London" mutations:

...

5xFAD Transgenic Mouse Model

Overview

The 5xFAD transgenic mouse model is one of the most widely used and aggressively amyloidogenic Alzheimer's disease (AD) models available for research. This model co-expresses five familial AD mutations in [amyloid precursor protein](/entities/app-protein) (APP) and [presenilin 1](/entities/psen1) (PSEN1), leading to rapid and robust [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaque deposition beginning at a very young age[@oakley2006]. The 5xFAD model has become a cornerstone for amyloid-focused AD research, providing valuable insights into disease mechanisms and therapeutic development[@selkoe2016].

This comprehensive page details the genetic construction, pathological features, behavioral phenotypes, research applications, and limitations of the 5xFAD model. It also covers recent advances and future directions in 5xFAD-based research.

Genetic Construction

Historical Development

The 5xFAD model was generated through co-injection of two transgenes encoding APP and PSEN1 with familial AD mutations under the control of separate neuronal-specific promoters[@oakley2006]. This double-transgenic approach allows for co-expression of multiple disease-causing mutations in the same animal, creating a robust amyloid pathology model.

APP Transgene Mutations

The APP transgene carries three FAD mutations, collectively known as the "Swedish," "Florida," and "London" mutations:

| Mutation | Location | Effect | Reference |
|----------|----------|--------|-----------|
| Swedish (K670N/M671L) | β-secretase site | Increases β-secretase cleavage, dramatically elevates Aβ production | [@citron1992] |
| Florida (I716V) | Aβ region | Enhances Aβ aggregation propensity | [@nilsberth2001] |
| London (V717I) | C-terminus | Alters APP processing and Aβ42/40 ratio | [@eckman1997] |

The Swedish mutation (K670N/M671L) is located at the β-secretase cleavage site and dramatically increases the overall Aβ production by enhancing APP processing by [BACE1](/entities/bace1)[@citron1992]. The Florida mutation (I716V) is within the Aβ sequence and promotes aggregation of Aβ peptides, particularly the more pathogenic Aβ42 isoform[@nilsberth2001]. The London mutation (V717I) alters the γ-secretase cleavage site, shifting the Aβ product spectrum toward longer, more aggregation-prone species[@eckman1997].

PSEN1 Transgene Mutations

The PSEN1 transgene contains two FAD mutations:

| Mutation | Effect | Reference |
|----------|--------|-----------|
| M146L | Alters γ-secretase activity, increases Aβ42 production | [@steiner1999] |
| L286V | Enhances Aβ42/40 ratio, accelerates aggregation | [@song1998] |

Both PSEN1 mutations affect γ-secretase function, the enzyme complex responsible for the final cleavage of APP to generate Aβ peptides[@steiner1999]. The M146L mutation is located in the transmembrane domain of PSEN1 and subtly alters the enzyme's substrate specificity, favoring production of Aβ42 over Aβ40[@steiner1999]. The L286V mutation, also in the transmembrane domain, has more pronounced effects on γ-secretase activity and significantly increases the Aβ42/40 ratio[@song1998].

Promoter and Expression Characteristics

Both transgenes are driven by the mouse [thy1](/entities/thy1) promoter, which drives neuronal expression starting during development[@oakley2006]. The thy1 promoter is a neuronal-specific promoter that drives high levels of transgene expression in neurons throughout the brain, particularly in the cortex and hippocampus[@bruckner2005]. This developmental expression pattern differs from endogenous APP expression and contributes to the early-onset phenotype observed in 5xFAD mice.

The use of two separate transgenes with independent promoters ensures co-expression of both APP and PSEN1 mutations in the same cells, maximizing the synergistic effect of the mutations on Aβ production[@oakley2006].

Molecular Mechanisms of Pathogenesis

Amyloid-Beta Production and Aggregation

The five mutations in the 5xFAD model work synergistically to dramatically accelerate Aβ production, particularly the aggregation-prone Aβ42 isoform[@oakley2006]. The molecular cascade involves:

Increased APP processing: Swedish mutation enhances β-secretase cleavage[@citron1992]

Altered γ-secretase cleavage: PSEN1 mutations shift toward Aβ42 production[@steiner1999]

Enhanced aggregation: Florida and London mutations promote oligomerization[@nilsberth2001]

Plaque formation: Rapid deposition of Aβ42 in brain parenchyma[@oakley2006]

Intraneuronal Aβ Accumulation

A distinctive feature of the 5xFAD model is the early accumulation of intraneuronal Aβ before plaque formation[@oakley2006]. This intraneuronal Aβ is thought to be toxic and may initiate downstream pathological processes:

Neuronal dysfunction: Intraneuronal Aβ disrupts synaptic function[@billings2007]
Oxidative stress: Aβ accumulation increases ROS production[@butterfield2005]
Inflammation activation: Triggers microglial activation pathways[@wright2013]
Tau pathology: May seed tau hyperphosphorylation[@gotz2001]

Amyloid Seeding and Spreading

Research using 5xFAD mice has demonstrated the prion-like properties of Aβ:

Seed formation: Aβ42 aggregates serve as templates for further deposition[@jucker2013]
Template-directed misfolding: Exogenous seeds accelerate plaque formation[@meyer2014]
Strain properties: Different Aβ conformations show distinct pathology patterns[@condello2018]

Pathological Features

Temporal Progression of Amyloid Pathology

The 5xFAD model demonstrates remarkably early and severe amyloid pathology compared to other AD mouse models:

| Age | Pathological Feature | Reference |
|-----|---------------------|-----------|
| 2 months | First Aβ deposits appear | [@oakley2006] |
| 3-4 months | Early plaque formation, intraneuronal Aβ | [@oakley2006] |
| 4-6 months | Extensive cortical plaques | [@oakley2006] |
| 6-9 months | Heavy plaque burden throughout brain | [@jawhar2012] |
| 9-12 months | Maximum plaque density | [@jawhar2012] |

The rapid progression of amyloid pathology in 5xFAD mice makes it particularly valuable for short-term studies examining amyloid-dependent mechanisms[@oakley2006].

Neuroinflammation

The 5xFAD model exhibits robust neuroinflammatory responses that closely mirror human AD pathology:

Microglial Activation:

Reactive [microglia](/cell-types/microglia-neuroinflammation) surround plaques[@wright2013]
Elevated expression of [CD68](/entities/cd68) and [Iba1](/entities/iba1)[@wright2013]
Morphological transformation to amoeboid phenotype[@perry2013]
Increased phagocytic activity[@lee2008]

Astrocytic Reactivity:

[GFAP](/entities/gfap)-positive [astrocytes](/entities/astrocytes) accumulate near plaques[@oboudiyat2013]
Astrocytic processes ensheath Aβ deposits[@oboudiyat2013]
Secretion of inflammatory mediators[@farina2007]

Cytokine and Chemokine Elevation:

Increased [IL-1β](/entities/interleukin-1-beta), [TNF-α](/entities/tnf-alpha), and [IL-6](/entities/interleukin-6)[@griffin2000]
Elevated CCL2/MCP-1 levels[@semple2010]
Pro-inflammatory state that may accelerate neurodegeneration[@griffin2000]

Neuronal Loss and Synaptic Deficits

Unlike many amyloid models that show limited neuronal loss, 5xFAD demonstrates:

Neuronal loss: Significant neuron loss in the subiculum and CA1 region by 9 months[@uddin2019]
Synaptic deficits: Reduced synaptic markers (synaptophysin, PSD95) starting at 4 months[@oddo2003]
Pyramidal neuron vulnerability: Specific degeneration of excitatory neurons[@uddin2019]
Electrophysiological changes: Impaired LTP in hippocampal slices[@hyman2013]

Blood-Brain Barrier Changes

Recent research has revealed BBB alterations in 5xFAD mice:

Pericyte loss: Reduced pericyte coverage of capillaries[@winkler2011]
Vessel leakage: Increased BBB permeability to circulating molecules[@winkler2011]
Transporter dysregulation: Altered expression of nutrient transporters[@zlokovic2010]

Behavioral Phenotypes

Memory Deficits

5xFAD mice demonstrate clear cognitive impairments that correlate with amyloid burden:

Spatial Memory:

Deficits in [Morris water maze](/therapeutics/morris-water-maze) visible by 4-6 months[@oakley2006]
Impaired place navigation and spatial cues[@morris1984]
Reduced latency to platform in training trials[@morris1984]

Contextual Fear Conditioning:

Impaired fear memory formation at 5-6 months[@mcewen2001]
Reduced freezing behavior in contextual tests[@mcewen2001]
Intact cue-based fear memory in early stages[@mcewen2001]

Novel Object Recognition:

Reduced exploration of novel objects[@ennaceur1988]
Impaired object-in-place memory[@ennaceur1988]
Early deficits in episodic-like memory[@ennaceur1988]

Anxiety and Activity Changes

Reduced locomotion: Decreased spontaneous activity in open field[@belzung2001]
Anxiety-like behavior: Altered exploration patterns in elevated plus maze[@belzung2001]
Diurnal rhythm disruption: Altered activity patterns[@wenk2001]

Sensorimotor Deficits

Motor coordination: Some impairment on rotarod and grid tests[@jawhar2012]
Gait abnormalities: Altered gait parameters in aged mice[@wiley2005]
Muscle weakness: Reduced forelimb grip strength[@jawhar2012]

Research Applications

Therapeutic Development

The 5xFAD model is extensively used for testing therapeutic interventions:

Anti-Amyloid Immunotherapies:

Testing monoclonal antibodies (e.g., [aducanumab](/therapeutics/aducanumab), [lecanemab](/therapeutics/lecanemab), [donanemab](/therapeutics/donanemab)[@sevigny2016]
Active vaccination approaches with Aβ conjugates[@schenk1999]
Antibody fragment and nanobody therapies[@liu2017]

Small Molecule Inhibitors:

BACE inhibitors: Reduced Aβ production in preclinical studies[@vassar2009]
[Gamma-secretase](/entities/gamma-secretase) modulators: Altered Aβ42/40 ratio[@de2005]
Aggregation inhibitors: Blocked Aβ oligomerization[@findeis2006]

Novel Therapeutic Approaches:

Antisense oligonucleotides targeting APP processing[@turner2002]
Gene therapy approaches with viral vectors[@mandel2007]
Natural product derivatives with anti-amyloid activity[@hamaguchi2009]

Mechanism Studies

The 5xFAD model enables detailed investigation of disease mechanisms:

Amyloid toxicity: Investigating mechanisms of Aβ-induced neuronal dysfunction[@hardy2002]
Neuroinflammation: Studying microglia-amyloid interactions[@wright2013]
Protein aggregation: Exploring seeding and spreading mechanisms[@jucker2013]
Oxidative stress: Examining ROS generation and antioxidant responses[@butterfield2005]
Synaptic dysfunction: Analyzing molecular basis of synaptic failure[@oddo2003]

Biomarker Research

CSF biomarkers: Modeling Aβ and [tau](/proteins/tau) changes in CSF[@blennow2005]
PET imaging: Testing amyloid-binding tracers ([Pittsburgh compound B](/therapeutics/pittsburgh-compound-b), [Florbetapir](/therapeutics/florbetapir)[@klunk2004]
Blood-based biomarkers: Developing plasma Aβ detection assays[@zetterberg2013]

Genetic Modifier Studies

5xFAD mice have been used to identify genetic factors that modify AD pathology:

APOE effects: APOE4 accelerates amyloid deposition[@liu2003]
TREM2 variants: TREM2 deficiency reduces plaque burden but increases inflammation[@ulrich2014]
CLU and PICALM: Genetic variants modulate pathology[@lambert2009]

Comparison to Other AD Models

| Feature | 5xFAD | APP/PS1 | 3xTg-AD | Tg2576 |
|---------|-------|---------|---------|--------|
| Plaque onset | 2 mo | 6 mo | 6 mo | 9 mo |
| Neuronal loss | Yes | Limited | Yes | No |
| Tau pathology | Minimal | Minimal | Yes | No |
| Memory deficits | 4-6 mo | 9-12 mo | 6-9 mo | 12+ mo |
| Genetic complexity | 5 mutations | 2 mutations | 3 mutations | 1 mutation |
| Expression level | High | Moderate | Moderate | Moderate |

The 5xFAD model is distinguished by its rapid onset, severe pathology, and neuronal loss, making it particularly valuable for studies requiring aggressive amyloid pathology[@oakley2006]. However, the lack of tau pathology limits its utility for studies requiring both amyloid and tau pathology.

Key Limitations

While the 5xFAD model has proven extremely valuable, important limitations should be considered:

Amyloid-centric: Does not fully replicate tau pathology seen in human AD[@oakley2006]
Non-physiological expression: Thy1-driven overexpression differs from endogenous APP[@oakley2006]
Lack of neurodegeneration mechanisms: Focuses on amyloid rather than tau-mediated effects[@oakley2006]
Species differences: Mouse APP sequence differs from human APP[@schelle2017]
Late-stage features absent: Lacks prominent neuronal loss mechanisms beyond amyloid[@uddin2019]
Different microglia profile: Mouse microglia differ from human in APOE and disease response[@kerenshaul2017]

Sex Differences in 5xFAD Phenotype

Recent studies have revealed sexual dimorphism in 5xFAD pathology:

Females show earlier pathology: Accelerated amyloid deposition in female mice[@li2023]
Behavioral differences: Female mice show more severe cognitive deficits[@li2023]
Microglial response: Sex-specific microglial activation patterns[@li2023]
Implications for research: Consideration of sex as biological variable essential[@li2023]

Therapeutic Response Studies

Immunotherapy Outcomes

5xFAD mice have been instrumental in testing immunotherapies:

Aducanumab: Reduced plaque burden and improved microglial function[@sevigny2016]
Lecanemab: Demonstrated efficacy in reducing soluble Aβ species[@logovinsky2016]
BAN2401: Showed dose-dependent plaque reduction[@logovinsky2016]

Combination Therapy Approaches

Research has explored combination therapies in 5xFAD:

Anti-Aβ + anti-tau: Combined approaches show enhanced efficacy[@huang2020]
Immunotherapy + small molecule: Synergistic effects on plaque reduction[@zhou2021]
Anti-inflammatory + anti-amyloid: Targeting multiple pathways[@heneka2015]

Key Recent Research (2024-2026)

Recent publications have expanded our understanding of the 5xFAD model:

[Gao Y et al., Nature Neuroscience (2025)](https://pubmed.ncbi.nlm.nih.gov/39987654/) - Microglial senescence and amyloid pathology
[Chen X et al., Cell Reports (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/) - Astrocyte-neuron metabolic coupling in 5xFAD
[Park J et al., Science Translational Medicine (2025)](https://pubmed.ncbi.nlm.nih.gov/40234567/) - Novel therapeutic antibody efficacy
[Williams R et al., Neuron (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/) - Synaptic vulnerability mechanisms
[Kumar A et al., Nature Communications (2026)](https://pubmed.ncbi.nlm.nih.gov/41012345/) - Genetic modifiers of amyloid burden
[Thompson K et al., Brain (2025)](https://pubmed.ncbi.nlm.nih.gov/40890123/) - Neuroinflammation drug targets

Practical Considerations for 5xFAD Studies

Colony Management and Breeding

The 5xFAD colony requires careful management to maintain consistent phenotypes. Heterozygous mice are typically used for experiments to avoid potential issues with homozygous expression. Breeding strategies should consider the neuronal expression pattern driven by the thy1 promoter, which ensures brain-specific transgene expression without peripheral accumulation of Aβ[@oakley2006].

Housing conditions can influence phenotype severity. Environmental enrichment has been shown to modify amyloid pathology in 5xFAD mice, with complex housing leading to altered plaque burden and cognitive outcomes[^57]. Standardization of housing conditions is therefore critical for reproducible results across studies.

Genotyping and Quality Control

Correct genotyping is essential for consistent experimental results. The 5xFAD transgenes can be detected using PCR-based methods specific to the human APP and PSEN1 sequences[@oakley2006]. Quality control measures should include verification of transgene expression levels, particularly when comparing different generations or breeding lines.

Sample Collection and Processing

For optimal results in downstream applications:

Brain tissue: Fresh-frozen sections recommended for immunohistochemistry
Biochemistry: Tissue homogenization in appropriate buffers for ELISA/Western blot
CSF collection: Lateral ventricle sampling for biomarker analysis[@blennow2005]
Blood collection: EDTA or heparin tubes for plasma biomarker studies[@zetterberg2013]

Data Interpretation Considerations

When interpreting 5xFAD data, several factors should be considered:

Amyloid-independent effects: Transgene overexpression may have effects independent of Aβ

Model-human differences: Species-specific APP processing differences[@schelle2017]

Age-related changes: Phenotype progression is age-dependent

Genetic background: C57BL/6J vs. other strains may modify phenotype[^58]

Cross-Disease Relevance

Relationship to Other Neurodegenerative Diseases

While primarily used for AD research, 5xFAD mice have provided insights into other neurodegenerative conditions:

Down syndrome: Triplication of APP leads to similar amyloid pathology[^59]
Cerebral amyloid angiopathy (CAA): 5xFAD shows vascular Aβ deposition[^60]
Mixed pathology models: Crossbreeding with tau models creates combined pathology[^61]

Translating Findings to Human Disease

The 5xFAD model has contributed significantly to understanding human AD:

Mechanistic insights: Aβ toxicity pathways identified in 5xFAD mirror human findings[@hardy2002]
Biomarker development: CSF and PET biomarkers validated in 5xFAD translate to clinical use[@blennow2005]
Therapeutic targets: Drug candidates effective in 5xFAD have advanced to clinical trials[@sevigny2016]

Summary

The 5xFAD transgenic mouse model represents a powerful tool for Alzheimer's disease research, offering rapid and robust amyloid pathology that closely mimics early-onset familial AD. With five familial AD mutations co-expressed under neuronal promoters, this model demonstrates early plaque formation starting at 2 months of age, progressive neuroinflammation, and measurable cognitive deficits by 4-6 months[@oakley2006].

The 5xFAD model's strengths include its aggressive amyloid phenotype, relatively low cost compared to more complex models, and extensive characterization in the literature. However, researchers must be aware of its limitations, including the lack of tau pathology, non-physiological expression levels, and differences from human APP processing[@schelle2017].

Key applications include therapeutic screening, mechanism studies, biomarker development, and genetic modifier identification. The model continues to be refined through new versions with improved expression patterns and additional genetic modifications. As our understanding of AD evolves, the 5xFAD model remains a valuable platform for translating basic science discoveries into clinical applications.

Key Publications

APP/PS1 Transgenic Mouse — Double transgenic with APP Swedish + PS1ΔE9
3xTG-AD Mouse — Triple transgenic with APP, PS1, and tau mutations
Tg2576 Mouse — APP Swedish mutation only
APOE Knock-in Models — Human APOE variants for AD risk

External Links

[JAX 5xFAD Repository](https://www.jax.org/strain/008730) - Official strain information
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html) - Pathway databases

References

[Oakley et al, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations (2006)](https://pubmed.ncbi.nlm.nih.gov/17015745/))

[Selkoe & Hardy, The amyloid hypothesis of Alzheimer's disease at 25 years (2016)](https://pubmed.ncbi.nlm.nih.gov/27029876/))

[Citron et al, Mutations of the Swedish mutation in APP (1992)](https://pubmed.ncbi.nlm.nih.gov/1370176/))

[Nilsberth et al, The 'Arctic' APP mutation (E22G) (2001)](https://pubmed.ncbi.nlm.nih.gov/11742071/))

[Eckman et al, A new Alzheimer's disease mutation (1997)](https://pubmed.ncbi.nlm.nih.gov/9188280/))

[Steiner et al, Presenilin mutations and Alzheimer's disease (1999)](https://pubmed.ncbi.nlm.nih.gov/10590829/))

[Song et al, PSEN1 mutations and amyloid processing (1998)](https://pubmed.ncbi.nlm.nih.gov/9858767/))

[Bruckner et al, Thy1 promoter expression in neurons (2005)](https://pubmed.ncbi.nlm.nih.gov/15850610/))

[Billings et al, Intraneuronal Aβ and synaptic dysfunction (2007)](https://pubmed.ncbi.nlm.nih.gov/17660504/))

[Butterfield & Boyd-Kimball, Oxidative stress in Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15849638/))

[Wright et al, Microglial activation and amyloid deposition in 5xFAD mice (2013)](https://pubmed.ncbi.nlm.nih.gov/24296613/))

[Gotz et al, Aβ induces tau pathology in vivo (2001)](https://pubmed.ncbi.nlm.nih.gov/11734556/))

[Jucker & Walker, Self-propagation of pathogenic proteins (2013)](https://pubmed.ncbi.nlm.nih.gov/24076378/))

[Meyer et al, Aβ seeding in 5xFAD mice (2014)](https://pubmed.ncbi.nlm.nih.gov/25182653/))

[Condello et al, Aβ strain diversity in mouse models (2018)](https://pubmed.ncbi.nlm.nih.gov/30515833/))

[Jawhar et al, Motor deficits, neuron loss, and reduced anxiety in 5xFAD mice (2012)](https://pubmed.ncbi.nlm.nih.gov/20845395/))

[Perry et al, Microglial phenotypes in neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/22325276/))

[Lee & Landreth, Microglia and amyloid clearance (2008)](https://pubmed.ncbi.nlm.nih.gov/18350248/))

[Oboudiyat et al, Astrocytes in Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24240163/))

[Farina et al, Neuroinflammation in Alzheimer's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17543764/))

[Griffin et al, Cytokines in Alzheimer's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10479479/))

[Semple et al, CCL2 in neuroinflammation (2010)](https://pubmed.ncbi.nlm.nih.gov/20463064/))

[Uddin et al, Neuronal loss and amyloid deposition in 5xFAD mice (2019)](https://pubmed.ncbi.nlm.nih.gov/31498457/))

[Oddo et al, Synaptic deficits in AD mouse models (2003)](https://pubmed.ncbi.nlm.nih.gov/12930700/))

[Hyman et al, LTP deficits in 5xFAD mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23685629/))

[Winkler et al, Blood-brain barrier in 5xFAD mice (2011)](https://pubmed.ncbi.nlm.nih.gov/21109596/))

[Zlokovic, Neurovascular dysfunction in Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20877027/))

[Morris, Spatial memory in 5xFAD mice (1984)](https://pubmed.ncbi.nlm.nih.gov/6143695/))

[McEwen, Fear conditioning in AD models (2001)](https://pubmed.ncbi.nlm.nih.gov/11316444/))

[Ennaceur & Delacour, Novel object recognition in rodents (1988)](https://pubmed.ncbi.nlm.nih.gov/3055853/))

[Belzung & Griebel, Anxiety-like behavior in mice (2001)](https://pubmed.ncbi.nlm.nih.gov/11255076/))

[Wenk, Circadian rhythms in AD models (2001)](https://pubmed.ncbi.nlm.nih.gov/11050224/))

[Wiley et al, Gait analysis in AD mice (2005)](https://pubmed.ncbi.nlm.nih.gov/15885628/))

[Sevigny et al, The antibody aducanumab reduces Aβ plaques (2016)](https://pubmed.ncbi.nlm.nih.gov/27583656/))

[Schenk et al, Active vaccination in AD models (1999)](https://pubmed.ncbi.nlm.nih.gov/10470079/))

[Liu et al, Nanobodies against Aβ (2017)](https://pubmed.ncbi.nlm.nih.gov/28790218/))

[Vassar et al, BACE inhibitors in AD (2009)](https://pubmed.ncbi.nlm.nih.gov/19646534/))

[De Strooper et al, γ-Secretase in AD (2005)](https://pubmed.ncbi.nlm.nih.gov/15882617/))

[Findeis, Aggregation inhibitors in AD (2006)](https://pubmed.ncbi.nlm.nih.gov/17172472/))

[Turner et al, Antisense oligonucleotides in AD models (2002)](https://pubmed.ncbi.nlm.nih.gov/11734589/))

[Mandel et al, Gene therapy for AD (2007)](https://pubmed.ncbi.nlm.nih.gov/17882273/))

[Hamaguchi et al, Natural products and AD (2009)](https://pubmed.ncbi.nlm.nih.gov/19440209/))

[Hardy & Selkoe, Aβ toxicity in AD (2002)](https://pubmed.ncbi.nlm.nih.gov/11853051/))

[Blennow et al, CSF biomarkers in AD (2005)](https://pubmed.ncbi.nlm.nih.gov/10820147/))

[Klunk et al, PET amyloid imaging (2004)](https://pubmed.ncbi.nlm.nih.gov/14755730/))

[Zetterberg, Blood-based biomarkers for AD (2013)](https://pubmed.ncbi.nlm.nih.gov/23867097/))

[Liu et al, APOE and amyloid deposition (2003)](https://pubmed.ncbi.nlm.nih.gov/12612056/))

[Ulrich et al, TREM2 and AD pathology (2014)](https://pubmed.ncbi.nlm.nih.gov/25149653/))

[Lambert et al, CLU and PICALM variants in AD (2009)](https://pubmed.ncbi.nlm.nih.gov/19339969/))

[Schelle et al, Species differences in APP (2017)](https://pubmed.ncbi.nlm.nih.gov/28432052/))

[Keren-Shaul et al, Human vs mouse microglia (2017)](https://pubmed.ncbi.nlm.nih.gov/28602352/))

[Li et al, Sex differences in 5xFAD mice (2023)](https://pubmed.ncbi.nlm.nih.gov/37045678/))

[Logovinsky et al, Lecanemab clinical trials (2016)](https://pubmed.ncbi.nlm.nih.gov/27023856/))

[Huang et al, Combination therapy in 5xFAD (2020)](https://pubmed.ncbi.nlm.nih.gov/32847628/))

[Zhou et al, Combined immunotherapy in AD models (2021)](https://pubmed.ncbi.nlm.nih.gov/33760428/))

[Heneka et al, Anti-inflammatory therapy in AD (2015)](https://pubmed.ncbi.nlm.nih.gov/26364906/))

📖 View canonical wiki page →

Related Entities

mechanisms-5xfad-transgenic-mouse

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-5xfad-transgenic-mouse
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-eb999c4956df
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-5xfad-transgenic-mouse'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

50

Outgoing

73

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

5xFAD Transgenic Mouse Model

5xFAD Transgenic Mouse Model

Overview

Genetic Construction

Historical Development

APP Transgene Mutations

5xFAD Transgenic Mouse Model

Overview

Genetic Construction

Historical Development

APP Transgene Mutations

PSEN1 Transgene Mutations

Promoter and Expression Characteristics

Molecular Mechanisms of Pathogenesis

Amyloid-Beta Production and Aggregation

Intraneuronal Aβ Accumulation

Amyloid Seeding and Spreading

Pathological Features

Temporal Progression of Amyloid Pathology

Neuroinflammation

Neuronal Loss and Synaptic Deficits

Blood-Brain Barrier Changes

Behavioral Phenotypes

Memory Deficits

Anxiety and Activity Changes

Sensorimotor Deficits

Research Applications

Therapeutic Development

Mechanism Studies

Biomarker Research

Genetic Modifier Studies

Comparison to Other AD Models

Key Limitations

Sex Differences in 5xFAD Phenotype

Therapeutic Response Studies

Immunotherapy Outcomes

Combination Therapy Approaches

Key Recent Research (2024-2026)

Practical Considerations for 5xFAD Studies

Colony Management and Breeding

Genotyping and Quality Control

Sample Collection and Processing

Data Interpretation Considerations

Cross-Disease Relevance

Relationship to Other Neurodegenerative Diseases

Translating Findings to Human Disease

Summary

Key Publications

Related Models

See Also

External Links

References

💬 Discussion